Oral semaglutide
Sold by Direct Meds · Oral tablet · every oral semaglutide record
Recorded initial charges
First month
$249
first month, including required fees on record. The published monthly rate excludes one-time and annual fees; introductory and conditional rates may change. Some fee details are unverified or unpublished; this sum does not establish the full amount payable.
| Medication · Month to month, sublingual · recorded initial monthly payment | $249 |
|---|
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| Month to month, sublingual “Plans start at $249/month for sublingual Semaglutide, and $297/month for injections.” | Per month$249 | Charged today$249 |
Price sources
- Month to month, sublingual · directmeds.com — read August 2026
This is a paid link. If you enroll through it, Treatment Registry may earn a commission. It does not change what we record, and it does not change the price you pay.
History
- September 2026 — $249
- September 2026 — $249
- August 2026 — Entry added to the register
Sourcing and terms
| Pharmacy | Not disclosed as of August 2026 |
|---|---|
| Prescriber | Asynchronous review |
| Cancellation | You may attempt to cancel a prescription order within 24 hours of placing it (if not yet received by the provider network). After 24 hours, prescription orders generally cannot be canceled. Subscriptions can be canceled anytime, but no refunds for medication already received. |
| Membership | None. “What you see is what you pay-no membership fees, no surprise charges, and no pressure.” |
| Consult fee | Not disclosed as of August 2026 |
Not yet checked: states.
Recorded from directmeds.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. August 2026 — Direct Meds carries an FDA warning letter, number 716822, issued September 2025 and published in FDA's warning-letter index, concerning the online sale and labeling of compounded semaglutide and tirzepatide. No FDA action has halted the business and it continues to operate. Most warning letters concern marketing and labeling claims rather than a finding that a company cannot trade, and we record them rather than treating them as a verdict.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.